血清趋化因子配体5水平与肌层浸润性膀胱癌患者术后复发的关系

Chemokine C-X-C motif ligand 5 levels in plasma can be used as a predictor of postoperative recurrence in patients with non muscle invasive bladder cancer

目的 探讨血清趋化因子配体5（CXCL5）的水平与膀胱癌患者术后复发的关系.方法 应用酶联免疫吸附试验法（ELISA）检测127例膀胱癌患者术前血清中CXCL5水平,根据术后病理检查结果将127例膀胱癌患者分为非肌层浸润性膀胱癌组（NMIBC组）和肌层浸润性膀胱癌组（MIBC组）,分析血清中CXCL5水平与临床病理特征的关系,并对患者进行随访,分析血清中CXCL5水平与术后复发的关系.结果 MIBC和存在淋巴结转移的患者血清中CXCL5水平[分别为（1 004.76±112.81） pg/ml和（993.48±115.83） pg/ml]显著高于NMIBC和淋巴结未转移患者[分别为（658.42 ±98.16） pg/ml和（653.89 ±67.44） pg/ml],且随组织学分级升高而升高[G1：（634.28±93.33） pg/ml、G2：（752.43±73.54） pg/ml、G3：（866.77±106.49） pg/ml;P＜0.05];根据ROC曲线,将CXCL5临界值定为817.8 pg/ml;MIBC患者血清中CXCL5≥＞817.8 pg/ml者无瘤生存率显著低于血清中CXCL5 ＜817.8 pg/ml患者（P＜0.05）.结论 检测膀胱癌患者血清中CXCL5水平有助于评估病情严重程度,检测血清中CXCL5水平有助于预测MIBC。

Objective Objective to investigate the relationship between the level of plasma Chemokine C-X-C motif ligand 5 （CXCL5） and the recurrence of patients with bladder cancer.Methods Using the enzyme-linked immune adsorption method （ELISA） for detection of 127 cases of bladder cancer patients with preoperative urinary CXCL5 levels,put the 127 patients with bladder cancer points into non muscle invasive bladder cancer was （NMIBC group） and muscular layer infiltration of bladder cancer group （MIBC） group according to the postoperative pathology,to analyze the relationship between plasma CXCL5 levels with clinical pathological parameters.And the patients were followed up,to analyze the relationship between the level of CXCL 5 in plasma and pathological parameters.Results The level of CXCL5 levels in the serum of MIBC and patients withe lymph node metastasis [respectively （1 004.76 ± 112.81） pg/ml and （993.48 ± 115.83） pg/ml] were significantly higher than that of NMIBC and lymph node transfer patients [respectively,（658.42 ± 98.16） pg/ml and （653.89 ± 67.44） pg/ml] and with grade increased and increased [G1：（634.28 ± 93.33） pg/ml,G2：（752.43 ± 73.54） pg/ml,G3：（866.77 ± 106.49） pg/ml;P 〈 0.05];according to the ROC curve,the critical value of CXCL5 positioning was 817.8 pg/ml;The disease-free survival rate of patients with CXCL5 level in serum lower than 817.8 pg/ml was significant lower than patients with CXCL5 level in serum greater or equal to 817.8 pg/ml.Conclusion CXCL5 in serum of patients with bladder cancer can be regarded as one of the indicators for assessing the severity of the disease,serum CXCL5 levels can be used as one of the indicators to predict the MIBC.